



**U.S. Department of Justice**

Office of Justice Programs

*Bureau of Justice Assistance*

---

Washington, D.C. 20531

November 8, 2018

*RE: Fiscal Year (FY) 2018 Comprehensive Opioid Abuse Site-based Program award*

Dear FY 2018 COAP PDMP grantee:

In response to requests that the Office of Justice Programs (OJP) clarify grant special conditions 43 and 45 under the Prescription Drug Monitoring Program (PDMP), please be advised that ensuring the protection of privacy and the security of patient information is a top priority for OJP and the Bureau of Justice Assistance (BJA). As such, BJA will not require PDMP award recipients to transfer data in a manner that would violate the Health Insurance Portability and Accountability Act or other applicable federal laws.

BJA understands and acknowledges that the terms and conditions of your award shall not require an award recipient to provide, disclose, or otherwise furnish confidential data, including Personally Identifiable Information, in violation of federal or state law. We intend to ensure full compliance with those terms and conditions.

Thank you for your inquiry regarding your award.

Sincerely,

  
Tracey Trautman  
Deputy Director